African Nations Resist U.S. Health Pacts

Zimbabwe, Zambia, and Kenya have recently challenged proposed health funding agreements with the United States, citing concerns over data sovereignty and equitable benefit sharing. In late February, Zimbabwe withdrew from a proposed five-year, $367 million U.S.

health funding agreement, objecting to provisions requiring extensive American access to sensitive health data and pathogen samples without guaranteed equitable access to resulting medical technologies. Similarly, Zambia is scrutinizing a proposed five-year, $1 billion U.S.-Zambia health partnership, which includes a controversial clause linking its termination to Zambia's failure to conclude a separate bilateral mineral compact with Washington.

Kenya's High Court suspended a comparable $2.5 billion agreement in December following a legal challenge regarding the potential exposure of sensitive health data without adequate safeguards under Kenya’s Data Protection Act. These disputes highlight a broader pattern within the U.S.

Background

"America First Global Health Strategy," which has led to over 20 memoranda of understanding with African governments, totaling nearly $20 billion in commitments from 2026 to 2030. A significant portion of this funding is expected to be co-financed by African governments.

The core controversy across these agreements, including one in Nigeria, revolves around U.S. demands for health data and pathogen samples.

This information is critical for the global bioeconomy, supporting vaccine platforms, pharmaceutical patents, and AI-driven drug discovery. African nations express concern that they may become upstream suppliers of biological information, while intellectual property and commercial profits remain concentrated in wealthier countries, echoing historical patterns of biomedical extractivism and colonial-era medical practices.